Genetic Future

Latest / page 2

My genetic future, part 2: results

For those who haven’t already heard via Twitter or other means, there’s a good reason I’ve been so quiet the past few weeks. My first collaborative genetic experiment with my wife – for which I presented some promising preliminary data back in February – finally generated results on August 28th: Figure 1: Tobias MacArthur We’re still…

The recent Government Accountability Office report into the direct-to-consumer genetic testing industry certainly made a splash: it took centre stage at a Congressional hearing on the industry, and garnered media headlines about “bogus” results being generated by testing companies. As I noted at the time of its release, the report is an obscenely one-sided affair:…

More huge news in the sequencing industry, following on from the public share offer from Pacific Biosciences – relative newcomer to the field, Ion Torrent, has just been bought by Life Technologies for an impressive US$375 million in cash and stock, with an option to increase by a further US$350 million if “certain technical and time-based…

The long-awaited public stock offer from third-generation sequencing technology company Pacific Biosciences has finally arrived (here’s the SEC filing, and coverage from Matthew Herper and GenomeWeb). PacBio has already raised almost US$400 million in venture capital, and aims to increase this by up to US$200 million from its share offering. The sheer scale of these…

In my previous post I quoted from Mary Carmichael’s excellent interview with two officials from the FDA, Alberto Gutierrez and Elizabeth Mansfield (part of her fantastic week-long DNA dilemma series, which you should read in full if you haven’t already). There are numerous nuggets of gold tucked away in this interview that warrant further analysis,…

Two days ago I reported a rumour that the FDA might have convinced genotyping chip provider Illumina to stop providing its products to direct-to-consumer genetic testing companies – a move that would effectively prevent these companies from being able to operate. The rumour seemed plausible at the time, based on two pieces of evidence. Firstly,…

Following up on the rumours I posted about yesterday regarding a potential bid by the FDA to choke of direct-to-consumer genetic testing companies’ supply of genotyping chips, I received the following statement by email from 23andMe’s PR firm: 23andMe is engaged in an ongoing process with the FDA. 23andMe understands that Illumina is also engaged…

Update 14:35 EDT 04/08/10: I just received a phone call from a 23andMe representative indicating that these rumours are not true; more details to follow once I have a written statement. Update 17:26 EDT 04/08/10: Here is the written statement from 23andMe’s PR firm: We will continue to work with Illumina as our discussion with the…

The whole idea of actually paying to read mainstream news online is rather alien to me, having grown up immersed in a world of free content readily available via Google News. Indeed, I can’t help but see free news as some kind of inviolable human right. Thus when the Times recently set up a paywall…

Personal genomics links

This week was pretty hectic, so there were plenty of useful or interesting links from the personal genomics world that I didn’t have time to write about in detail. Feel free to share your own suggestions in the comments. Responses to the Congress/FDA crack-downAs all of you will be aware, the big news this week…